What Is GLP-3? The Triple Agonist Metabolic Peptide Naming Convention Explained

What is GLP-3 triple agonist metabolic peptide Durham Peptides Canada

The term "GLP-3" has emerged in research peptide discussions as an informal name for triple agonist metabolic peptides — particularly retatrutide. The naming follows the progression researchers and writers have used to describe the metabolic peptide field's evolution: GLP-1 (single receptor agonist like semaglutide), then dual agonist (GLP-1 + GIP, like tirzepatide), and now what some refer to as "GLP-3" (triple agonist activating GLP-1, GIP, and glucagon receptors, like retatrutide). But "GLP-3" isn't actually a formal scientific designation — it's a colloquial naming convention that's worth understanding for Canadian researchers navigating the metabolic peptide research field.

This article explains what "GLP-3" actually means, why the term has emerged, what it does and doesn't refer to scientifically, and how Canadian researchers should understand triple agonist metabolic peptides like retatrutide.

For broader coverage, see Triple Agonist Peptides Explained and What Is Retatrutide?.

The Quick Answer

"GLP-3" is an informal naming convention that some sources use to describe triple agonist metabolic peptides — peptides that activate three receptors simultaneously: GLP-1, GIP, and glucagon receptors. The term most commonly refers to retatrutide.

Important context: "GLP-3" is not a formal scientific or pharmacological designation. The compound called retatrutide is technically a "GLP-1/GIP/glucagon triple agonist" or "triple receptor agonist." The "GLP-3" naming is a marketing-friendly shorthand that's emerged because it follows the intuitive progression from "GLP-1" to "GLP-3" — implying a third generation of metabolic peptide research.

For Canadian researchers, understanding both the colloquial term ("GLP-3") and the formal scientific designation ("triple agonist") matters because:

• Both terms appear in research peptide market discussions

• The colloquial term can be misleading about the actual receptor pharmacology

• The formal designation more accurately describes the compound's mechanism

Why "GLP-3" Has Emerged as a Term

The metabolic peptide research field has progressed through identifiable generations, and naming conventions have followed:

Generation 1: GLP-1 receptor agonists. The original incretin peptide research category. Compounds like semaglutide activate the single GLP-1 receptor. Often called simply "GLP-1 agonists" in popular discussion.

Generation 2: Dual agonists. Compounds like tirzepatide activate two receptors simultaneously — GLP-1 and GIP. Various names have emerged: "dual agonist," "GLP-1/GIP agonist," sometimes "GLP-2" (though this is also informal and arguably misleading).

Generation 3: Triple agonists. Compounds like retatrutide activate three receptors simultaneously — GLP-1, GIP, and glucagon. The "GLP-3" terminology emerged as the natural-sounding extension of the "GLP-1, GLP-2, GLP-3" naming progression.

The progression is intuitive but technically misleading. "GLP-1" specifically refers to a particular receptor, and "GLP-2" already has an entirely separate scientific meaning (a different receptor system, not relevant to the dual agonist research category). Calling tirzepatide "GLP-2" or retatrutide "GLP-3" doesn't accurately describe their pharmacology.

The formal scientific terminology — "single agonist," "dual agonist," "triple agonist" — is more accurate and is preferred in published research literature.

What "GLP-3" Actually Refers To: Retatrutide

When "GLP-3" appears in research peptide discussions, the compound being referred to is almost always retatrutide.

Retatrutide structure and mechanism:

• Approximately 39-amino-acid synthetic peptide with fatty acid conjugation

• Activates GLP-1 receptors (like semaglutide)

• Activates GIP receptors (like tirzepatide)

• Additionally activates glucagon receptors (the third receptor that makes it a triple agonist)

• Currently in advanced clinical research with substantial published clinical data

The "third receptor" in retatrutide's mechanism is the glucagon receptor. Glucagon's effects on energy expenditure and glucose metabolism complement the incretin pathway in ways that have been explored in published research literature.

For complete coverage of retatrutide specifically, see What Is Retatrutide?. Available in the Durham Peptides catalog as Retatrutide 10mg.

Why the Triple Agonist Approach

The progression from single-receptor compounds through dual-receptor to triple-receptor approaches reflects a research-grounded principle: complementary receptor pathways can produce additive or synergistic effects in research that single-receptor compounds can't achieve.

The biological reasoning:

GLP-1 receptors mediate glucose-dependent insulin secretion, slow gastric emptying, and influence appetite signaling.

GIP receptors mediate different aspects of incretin response — different signaling cascade, different downstream effects. Combining GLP-1 and GIP activation engages two complementary receptor systems.

Glucagon receptors add a third metabolic axis. Glucagon's effects on energy expenditure and glucose metabolism complement the incretin pathway in ways explored in published research literature.

The published research literature has documented enhanced effects with dual and triple agonist mechanisms compared to single-receptor compounds in research contexts.

For broader research peptide context, see Why Researchers Are Looking at Tirzepatide and Retatrutide.

The "GLP-3 Canada" Search Pattern

Canadian researchers searching for "GLP-3" or "GLP-3 Canada" are typically looking for one of three things:

1. Information about retatrutide specifically — most "GLP-3" searches resolve to retatrutide content

2. Comparison to GLP-1 compounds — wanting to understand how the "next generation" differs from the existing semaglutide/tirzepatide research

3. Canadian-domestic supply — researchers wanting to source the compound from Canadian-domestic suppliers

For Canadian researchers, retatrutide is available in the Durham Peptides catalog with Canadian-domestic shipping and Janoshik third-party testing. See Buy Retatrutide in Canada and Retatrutide Price in Canada.

The "Triple Antagonist" vs "Triple Agonist" Confusion

A common typo in search queries: "triple antagonist peptide" when the searcher means "triple agonist peptide." The two terms are pharmacological opposites:

Agonist. A compound that activates a receptor — promoting the receptor's signaling activity.

Antagonist. A compound that blocks a receptor — preventing the receptor's signaling activity.

Retatrutide is a triple agonist — it activates GLP-1, GIP, and glucagon receptors. It is NOT a triple antagonist (which would mean it blocks those receptors, the opposite mechanism).

The "antagonist" typo appears frequently in search queries because the words sound similar, but the pharmacological distinction matters. Triple agonist = activates three receptors. Triple antagonist = blocks three receptors. The metabolic peptide research category is built on agonism, not antagonism.

How GLP-3 Differs from GLP-1

For Canadian researchers comparing GLP-1 (semaglutide) to "GLP-3" (retatrutide):

Feature	GLP-1 (Semaglutide)	"GLP-3" (Retatrutide)
Receptor activation	Single (GLP-1 only)	Triple (GLP-1 + GIP + glucagon)
Mechanism complexity	Single pathway	Three complementary pathways
Published clinical data	Extensive (FDA approved formulations)	Substantial (Phase 3 ongoing as of 2026)
Manufacturing complexity	Lower than retatrutide	Higher (more amino acids, fatty acid conjugation)
Research peptide pricing	Lower per mg	Higher per mg

Both compounds engage incretin biology research, but retatrutide engages additional pathways that semaglutide doesn't touch.

For complete comparison, see Retatrutide vs Tirzepatide vs Semaglutide.

Frequently Asked Questions

What does GLP-3 stand for? "GLP-3" is an informal naming convention for triple agonist metabolic peptides. It doesn't actually stand for "glucagon-like peptide 3" in the formal scientific sense — the term has emerged as a colloquial extension of the "GLP-1, GLP-2, GLP-3" naming pattern.

Is GLP-3 a real scientific term? No, not in the formal pharmacological sense. The accurate scientific terminology is "triple agonist" or "GLP-1/GIP/glucagon triple receptor agonist." The "GLP-3" naming is colloquial.

What compound does GLP-3 refer to? Retatrutide is the most common compound referred to as "GLP-3" in research peptide discussions.

How is GLP-3 different from GLP-1? GLP-1 (like semaglutide) activates only the GLP-1 receptor. "GLP-3" (retatrutide) activates three receptors: GLP-1, GIP, and glucagon. Different mechanism complexity and different research applications.

What does "triple agonist" mean? A triple agonist activates three receptors simultaneously. For retatrutide, the three receptors are GLP-1, GIP, and glucagon.

What's the difference between "triple agonist" and "triple antagonist"? Opposite mechanisms. Triple agonist activates three receptors. Triple antagonist blocks three receptors. Retatrutide is a triple agonist (activates), not a triple antagonist (blocks).

Does Durham Peptides sell GLP-3 (retatrutide)? Yes. Retatrutide 10mg is available in the Durham Peptides catalog with Canadian-domestic shipping and Janoshik third-party testing.

Is GLP-3 (retatrutide) available in Canada? Yes. Retatrutide is available as a research peptide from Canadian-domestic suppliers including Durham Peptides. It is not approved by Health Canada for therapeutic use and operates under research-use-only framing. See Are Peptides Legal in Canada?.

Is retatrutide FDA-approved? As of 2026, retatrutide has not received FDA approval. The compound is in advanced clinical research with substantial published clinical data. Research peptide formulations are sold under research-use-only framing, separate from any future pharmaceutical approval pathway.

Is GLP-3 better than GLP-1? Different mechanisms for different research questions. The triple agonist approach engages additional receptor pathways that single agonists don't, but "better" depends on what research question is being addressed.

Why is retatrutide more expensive than semaglutide? Manufacturing complexity. Retatrutide is approximately 39 amino acids with fatty acid conjugation; semaglutide is 31 amino acids with fatty acid conjugation. Larger sequence and additional structural complexity translate to higher per-mg cost. See Why Some Peptides Cost More Than Others.

What's coming after GLP-3? The metabolic peptide research field continues to develop. Quad agonists (four receptors), additional receptor combinations, and entirely new pathway approaches are all in various stages of research. The naming conventions will likely evolve alongside the compounds.

Final Thoughts

"GLP-3" is a colloquial naming convention that's emerged for triple agonist metabolic peptides like retatrutide. While not a formal scientific designation, the term reflects the intuitive progression researchers have observed in the metabolic peptide field — from single-receptor GLP-1 compounds, through dual agonists like tirzepatide, to triple agonists like retatrutide.

For Canadian researchers, the practical takeaways:

1. "GLP-3" usually refers to retatrutide

2. The accurate scientific term is "triple agonist" or "triple receptor agonist"

3. The triple agonist mechanism activates GLP-1, GIP, and glucagon receptors simultaneously

4. Retatrutide is available from Canadian-domestic suppliers including Durham Peptides

5. Research-use-only framing applies to all metabolic research peptides

For continued reading, see Triple Agonist Peptides Explained, What Is Retatrutide?, Buy Retatrutide in Canada, Retatrutide vs Tirzepatide vs Semaglutide, and Why Researchers Are Looking at Tirzepatide and Retatrutide.

Browse the complete Durham Peptides catalog at durhampeptides.ca/category/all-products. View all Janoshik-verified COAs at durhampeptides.ca/lab-results.

Selected References

1. Coskun T, Urva S, Roell WC, et al. LY3437943, a Novel Triple Glucagon, GIP, and GLP-1 Receptor Agonist for Glycemic Control and Weight Loss. Cell Metabolism. 2022;34(9):1234-1247. https://pubmed.ncbi.nlm.nih.gov/35985340/

2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/

3. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology. 2019;10:155. https://pubmed.ncbi.nlm.nih.gov/31031702/

4. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist. Molecular Metabolism. 2018;18:3-14. https://pubmed.ncbi.nlm.nih.gov/30473097/

5. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018;27(4):740-756. https://pubmed.ncbi.nlm.nih.gov/29617641/

6. Müller TD, Finan B, Bloom SR, et al. Glucagon-like Peptide 1 (GLP-1). Molecular Metabolism. 2019;30:72-130. https://pubmed.ncbi.nlm.nih.gov/31767182/

All products sold by Durham Peptides are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease. This article is informational and does not constitute medical advice.